EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, TransCode Therapeutics's enterprise value is $0.04 Mil.
TransCode Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, TransCode Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for TransCode Therapeutics's EV-to-Revenue or its related term are showing as below:
RNAZ's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.17 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TransCode Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, TransCode Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransCode Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where TransCode Therapeutics's EV-to-Revenue falls into.
TransCode Therapeutics's current Enterprise Value is $0.04 Mil.
TransCode Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransCode Therapeutics's share price for today is $6.97.
TransCode Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransCode Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of TransCode Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RNAZ has been successfully added to your 